PCMA Blog
ICYMI: Medicare “Delinking” Does Not Result In Savings, Increases Costs For Seniors And Taxpayers
As a so-called “delinking” measure continues to be discussed in Congress, specifically in the Medicare Part D program, it’s important
Joe Grogan: Congress Wants A Better Value. So Why Are They Eliminating Performance Based Payment?
The House Ways and Means Committee will vote today on legislation that will include a so-called “delinking” policy in Medicare.
“Delinking” Proposal Increases Drug Costs For Medicare Beneficiaries And Taxpayers, Hands $10 Billion Giveaway To Big Pharma
The House Ways and Means Committee will vote tomorrow, May 8, on legislation that will include a so-called “delinking” policy
ICYMI: RealClearHealth: JC Scott: Let’s Get Drug Pricing Legislation Right
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association (PCMA), highlights the opportunity
Patient Access and Insulin: Market Forces, Innovative PBM Programs Lowering Costs for Patients
The insulin market today is not the market of five years ago. The insulin market of the 2010s was defined
Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics
“In effect, the era of high list prices and high rebates for insulin is over” In case you missed it,
Economists Ike Brannon and Anthony Lo Sasso: The Real Challenge Facing Independent Pharmacies
As independent pharmacies conduct a “Fly-In” in Washington D.C this week, they will undoubtedly double-down on support for policies targeting
What They Are Saying: PBMs Help Businesses, Families, And Patients Save On Rx Costs, Allow Employers To Offer Competitive Benefits
Voices from around the nation, including small business owners and concerned citizens, have sounded the alarm on proposals targeting pharmacy
Sorry, no posts matched your criteria.